Combined use of PRAME inhibitors and HDAC inhibitors
US7928081B2 · kind B2 · utility
1Cited by
0References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 27, 2005 |
| Grant date | Apr 19, 2011 |
| Priority date | — |
| Expiry date | Aug 16, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.